Congenital Heart Disease (CHD) Global Market Report 2025
상품코드:1703203
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 200 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
선천성 심장병(CHD) 시장 규모는 향후 수년간 강력한 성장세를 보이며 2029년까지 연평균 9.7%의 연평균 복합 성장률(CAGR)로 70억 5,000만 달러에 달할 것으로 예상됩니다. 예측 기간 중의 성장은 개발도상국의 의료 서비스 접근성 확대, 심장 영상 기술의 지속적인 혁신, 조기 발견 및 조기 치료를 위한 인식 제고 캠페인 증가, 전 세계 의료비 증가, 맞춤형 의료의 발전 등에 기인합니다. 예측 기간 중 주요 동향으로는 최소침습 수술 기술의 채택, 원격 환자 모니터링 및 진료를 위한 원격의료의 활용 확대, 개인 맞춤형 치료 접근법에 대한 수요 증가, 기능성과 수명이 강화된 혁신적인 이식형 장비의 개발, 진단 및 치료 과정에 인공지능과 머신러닝의 통합 등이 있습니다. 등을 들 수 있습니다.
모성 당뇨병의 유병률 증가는 향후 선천성 심장병(CHD) 시장 확대를 촉진할 것으로 예상됩니다. 임신성 당뇨병(GDM)으로도 알려진 모성 당뇨병은 임신 전 당뇨병이 없던 여성이 임신 중에 발병하는 질환입니다. 주로 좌식 생활과 식습관의 변화, 가임기 여성의 비만율 증가 등 생활습관의 변화로 인해 발생합니다. 산모의 혈당 수치가 높아지면 태아의 심장 발달을 방해하므로 산모의 당뇨병은 아기의 선천성 심장병(CHD) 위험을 증가시킬 수 있습니다. 높은 포도당 수치는 아기의 정상적인 심장 형성에 영향을 미쳐 CHD의 가능성을 높입니다. 예를 들어 2023년 10월 영국 정부 기관인 국립보건서비스(National Health Service)는 2형 당뇨병 진단을 받은 여성의 임신 부작용이 2021년 4.9%에서 2022년 6.6%로 증가했다고 보고했습니다. 그 결과, 산모의 당뇨병 환자 수 증가가 선천성 심장병(CHD) 시장 성장에 기여하고 있습니다.
선천성 심장질환 시장의 주요 기업은 환자의 예후와 삶의 질을 향상시키기 위해 비수술적 심장판막의 기술 혁신을 추진하고 있습니다. 비수술적 심장판막은 경피적 카테터라고도 불리며, 기존의 개심술 없이 심장판막증을 치료하는 의료기기입니다. 예를 들어 2023년 2월 미국의 의료 기술 기업 메드트로닉(Medtronic)은 Harmony Transcatheter Pulmonary Valve(TPV) 시스템을 재출시했습니다. 개심술을 대체할 수 있는 최소 침습적인 이 시스템은 선천성 심장질환, 특히 선천성 또는 수술로 교정된 우심실 유출로(RVOT) 이상을 가진 환자들을 위한 것입니다. 이 밸브는 오른쪽으로 설계된 최초의 FDA 승인 밸브이며, 중증 폐동맥 판막 역류 환자에게 비수술적 솔루션을 제공합니다. Harmony TPV 시스템은 2021년 미국 FDA의 승인을 받아 자발적 회수 후 재판매될 예정이며, 이는 선천성 심장병 환자를 위한 솔루션을 발전시키기 위한 메드트로닉의 헌신을 강조합니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 신형 코로나바이러스 및 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 선천성 심질환(CHD) PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 선천성 심질환(CHD) 시장 : 성장률 분석
세계의 선천성 심질환(CHD) 시장 실적 : 규모와 성장, 2019-2024
세계의 선천성 심질환(CHD) 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 선천성 심질환(CHD) TAM(Total Addressable Market)
제6장 시장 세분화
세계의 선천성 심질환(CHD) 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
심장판막 결함
심장벽 결함
혈관 결함
기타 유형
세계의 선천성 심질환(CHD) 시장 : 진단별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
심전도
흉부 X선 사진
심장 초음파 검사
경식도 심장 초음파 검사
맥박산소측정
운동 부하 시험
심장 CT 스캔 또는 자기공명영상 검사(MRI)
심장 카테터 검사
기타 진단
세계의 선천성 심질환(CHD) 시장 : 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
IC(Interventional Cardiology)
심장 수술
원격의료
약물 관리
라이프스타일 변경
세계의 선천성 심질환(CHD) 시장 : 연령층별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
유아
어린이
청소년
성인
세계의 선천성 심질환(CHD) 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원과 진료소
진단 센터
외래 수술 센터
조사·학술기관
세계의 선천성 심질환(CHD) 시장, 심장판막 결손의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
대동맥판 협착증
폐동맥판 협착증
승모판 일탈증
삼첨판 결손증
판막 역류
세계의 선천성 심질환(CHD) 시장, 심장벽결손의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
심방중격결손증(ASD)
심실중격결손증(VSD)
방중격결손증(AVSD)
좌심저형성 증후군(HLHS)
파로4징증(TOF)
세계의 선천성 심질환(CHD) 시장, 혈관 결손의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
대동맥협착증
동맥관개존증(PDA)
폐동맥협착
대혈관전위증(TGA)
동맥간
세계의 선천성 심질환(CHD) 시장, 기타 유형의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
단심실 결손증
엡스타인 기형
총허파정맥 환류 이상증(TAPVR)
관상동맥 이상
허파정맥 폐색증
제7장 지역별·국가별 분석
세계의 선천성 심질환(CHD) 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 선천성 심질환(CHD) 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
선천성 심질환(CHD) 시장 : 경쟁 구도
선천성 심질환(CHD) 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
Novartis AG Overview, Products and Services, Strategy and Financial Analysis
Medtronic Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
Siemens Healthineers
Philips Healthcare
Roche Diagnostics International Ltd.
Boston Scientific Corp.
Laboratory Corporation of America Holdings(LabCorp)
Terumo Corporation
Mindray Medical International Limited
Canon Medical Systems Corporation
Masimo Corporation
Neusoft Corp.
Carestream Health
Midmark Corporation
Contec Medical Systems
Randox Laboratories Ltd.
Schiller AG
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
선천성 심질환(CHD) 시장 2029 : 새로운 기회를 제공하는 국가
선천성 심질환(CHD) 시장 2029 : 새로운 기회를 제공하는 부문
선천성 심질환(CHD) 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁의 전략
제36장 부록
KSA
영문 목차
영문목차
Congenital heart disease (CHD) encompasses a spectrum of birth defects affecting the structure and function of the heart present at birth. These defects may involve abnormalities in the heart walls, valves, arteries, and veins near the heart. Treatment for CHD varies depending on the type and severity of the defect and may include medications, catheter-based interventions, open-heart surgery, or heart transplantation.
The primary types of congenital heart disease (CHD) include heart valve defects, heart wall defects, blood vessel defects, and others. Heart valve defects entail abnormalities or malfunctions in the heart valves, which regulate blood flow within the heart. Diagnosis methods may include electrocardiograms, chest X-rays, echocardiograms, transesophageal echocardiograms, pulse oximetry, exercise stress tests, cardiac computed tomography (CT) scans, magnetic resonance imaging (MRI), cardiac catheterization, among others. Treatment options range from interventional cardiology procedures to cardiac surgery, medication management, telemedicine, and lifestyle modifications. CHD affects individuals across all age groups, including infants, children, adolescents, and adults, who receive treatment in hospitals, clinics, diagnostic centers, ambulatory surgical centers, and research and academic institutions.
The congenital heart disease market research report is one of a series of new reports from The Business Research Company that provides congenital heart disease market statistics, including congenital heart disease industry global market size, regional shares, competitors with a congenital heart disease market share, detailed congenital heart disease market segments, market trends and opportunities, and any further data you may need to thrive in the congenital heart disease industry. This congenital heart disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The congenital heart disease (CHD) market size has grown rapidly in recent years. It will grow from $4.42 billion in 2024 to $4.87 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to the increased prevalence of risk factors such as obesity and smoking, improved diagnostic technologies, expanded geriatric population, heightened awareness campaigns, enhanced reimbursement policies, and increased investment in research and development.
The congenital heart disease (CHD) market size is expected to see strong growth in the next few years. It will grow to $7.05 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to expanding access to healthcare services in developing regions, continuous innovation in cardiac imaging technologies, growing awareness campaigns promoting early detection and treatment, rising healthcare expenditure globally, and the development of personalized medicine. Major trends in the forecast period include adoption of minimally invasive surgical techniques, expanding use of telemedicine for remote patient monitoring and consultations, rising demand for personalized treatment approaches, development of innovative implantable devices with enhanced functionality and longevity, integration of artificial intelligence and machine learning in diagnostic and therapeutic processes.
The growing prevalence of maternal diabetes is expected to drive the expansion of the congenital heart disease (CHD) market in the future. Maternal diabetes, also known as gestational diabetes mellitus (GDM), develops during pregnancy in women who did not have diabetes before conceiving. It is primarily caused by lifestyle changes, such as sedentary behavior, poor dietary habits, and rising obesity rates among women of childbearing age. Maternal diabetes can increase the risk of congenital heart disease (CHD) in infants, as elevated blood sugar levels in the mother can disrupt fetal heart development. The high glucose levels affect the normal formation of the baby's heart, leading to a higher likelihood of CHD. For example, in October 2023, the National Health Service, a UK government agency, reported that adverse pregnancy outcomes for women diagnosed with type 2 diabetes increased from 4.9% in 2021 to 6.6% in 2022. As a result, the rising number of maternal diabetes cases is contributing to the growth of the congenital heart disease (CHD) market.
Key players in the congenital heart disease market are innovating non-surgical heart valves to enhance patient outcomes and quality of life. Non-surgical heart valves, also known as transcatheters, are medical devices treating heart valve diseases without conventional open-heart surgery. For instance, in February 2023, Medtronic, a US-based medical technology company, reintroduced its Harmony Transcatheter Pulmonary Valve (TPV) System. This system, a minimally invasive alternative to open-heart surgery, addresses patients with congenital heart disease, particularly those with native or surgically repaired right ventricular outflow tract (RVOT) anomalies. It stands as the first FDA-approved valve designed for the right side, offering a non-surgical solution for severe pulmonary valve regurgitation patients. The Harmony TPV System received U.S. FDA approval in 2021 and was reintroduced following a voluntary recall, underscoring Medtronic's dedication to advancing solutions for congenital heart disease patients.
In May 2024, Novartis Healthcare Private Limited, a Switzerland-based pharmaceutical company, partnered with Ayala Healthcare Holdings, Inc. (AC Health) to launch an Integrated Cardiovascular and Cancer Care initiative. This collaboration aims to expand access to innovative treatments for breast cancer, heart failure, and high cholesterol. Ayala Healthcare Holdings, Inc. (AC Health) is a Philippines-based pharmaceutical company specializing in generic drugs.
Major companies operating in the congenital heart disease (CHD) market are Pfizer Inc., AstraZeneca Plc, Abbott Laboratories, Novartis AG, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Neusoft Corp., Carestream Health, Midmark Corporation, Contec Medical Systems, Randox Laboratories Ltd., Schiller AG, BPL Medical Technologies, Compumedics Limited, Biocare Medical, Bionet America Inc., Nasan Medical Electronics Pvt Ltd
North America was the largest region in the congenital heart disease (CHD) market in 2024. The regions covered in the congenital heart disease (CHD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the congenital heart disease (CHD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The congenital heart disease (CHD) market consists of revenues earned by entities by providing services such as medical consultations, diagnostic tests, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The congenital heart disease (CHD) market also includes sales of cardiac implants such as pacemakers, implantable cardioverter-defibrillators (ICDs), and ventricular assist devices (VADs). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Congenital Heart Disease (CHD) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on congenital heart disease (chd) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for congenital heart disease (chd) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The congenital heart disease (chd) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Heart Valve Defects; Heart Wall Defects; Blood Vessel Defects; Other Types
2) By Diagnosis: Electrocardiogram; Chest X-ray; Echocardiogram; Transesophageal Echocardiogram; Pulse Oximetry; Exercise Stress Test; Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI); Cardiac Catheterization; Other Diagnosis
2) By Heart Wall Defects: Atrial Septal Defect (ASD); Ventricular Septal Defect (VSD); Atrioventricular Septal Defect (AVSD); Hypoplastic Left Heart Syndrome (HLHS); Tetralogy of Fallot (TOF)
3) By Blood Vessel Defects: Coarctation Of The Aorta; Patent Ductus Arteriosus (PDA); Pulmonary Artery Stenosis; Transposition Of The Great Arteries (TGA); Truncus Arteriosus
4) By Other Types: Single Ventricle Defects; Ebstein's Anomaly; Total Anomalous Pulmonary Venous Return (TAPVR); Coronary Artery Anomalies; Pulmonary Venous Obstruction
3. Congenital Heart Disease (CHD) Market Trends And Strategies
4. Congenital Heart Disease (CHD) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Congenital Heart Disease (CHD) Growth Analysis And Strategic Analysis Framework
5.1. Global Congenital Heart Disease (CHD) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Congenital Heart Disease (CHD) Market Growth Rate Analysis
5.4. Global Congenital Heart Disease (CHD) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Congenital Heart Disease (CHD) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Congenital Heart Disease (CHD) Total Addressable Market (TAM)
6.1. Global Congenital Heart Disease (CHD) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Heart Valve Defects
Heart Wall Defects
Blood Vessel Defects
Other Types
6.2. Global Congenital Heart Disease (CHD) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Electrocardiogram
Chest X-ray
Echocardiogram
Transesophageal Echocardiogram
Pulse Oximetry
Exercise Stress Test
Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI)
Cardiac Catheterization
Other Diagnosis
6.3. Global Congenital Heart Disease (CHD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Interventional Cardiology
Cardiac Surgery
Telemedicine
Medication Management
Lifestyle Modifications
6.4. Global Congenital Heart Disease (CHD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Infants
Children
Adolescents
Adults
6.5. Global Congenital Heart Disease (CHD) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Diagnostic Centers
Ambulatory Surgical Centers
Research And Academic Institutions
6.6. Global Congenital Heart Disease (CHD) Market, Sub-Segmentation Of Heart Valve Defects, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Aortic Valve Stenosis
Pulmonary Valve Stenosis
Mitral Valve Prolapse
Tricuspid Valve Defects
Valve Regurgitation
6.7. Global Congenital Heart Disease (CHD) Market, Sub-Segmentation Of Heart Wall Defects, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Atrial Septal Defect (ASD)
Ventricular Septal Defect (VSD)
Atrioventricular Septal Defect (AVSD)
Hypoplastic Left Heart Syndrome (HLHS)
Tetralogy of Fallot (TOF)
6.8. Global Congenital Heart Disease (CHD) Market, Sub-Segmentation Of Blood Vessel Defects, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Coarctation Of The Aorta
Patent Ductus Arteriosus (PDA)
Pulmonary Artery Stenosis
Transposition Of The Great Arteries (TGA)
Truncus Arteriosus
6.9. Global Congenital Heart Disease (CHD) Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Single Ventricle Defects
Ebstein's Anomaly
Total Anomalous Pulmonary Venous Return (TAPVR)
Coronary Artery Anomalies
Pulmonary Venous Obstruction
7. Congenital Heart Disease (CHD) Market Regional And Country Analysis
7.1. Global Congenital Heart Disease (CHD) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Congenital Heart Disease (CHD) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
